Solid lipid nanoparticles were at the frontline of the rapid development of nanotechnology, with several potential applications in drug administration. Because of their unique size-dependent properties, solid lipid nanoparticles have the potential to produce innovative treatments. The capacity to incorporate drugs into nanocarriers allows for the creation of a revolutionary drug delivery prototype that might be utilized for targeting novel drugs to the brain. RZT benzoate intra nasal formulation would be a practical, non-invasive, & alternative method of fast drug delivery to the brain for migraine treatment. Poloxamer-containing solid lipid nanoparticles having mucoadhesive characteristics improve drug absorption by increasing contact duration at the nasal mucosa. Shape, surface morphology, particle size, FTIR, DSC, X-ray diffraction tests, drug entrapment, total drug content, and in vitro drug release studies were all performed on RZT-loaded solid lipid nanoparticles created utilizing a modified solvent diffusion method. There was a wide range in particle size from 124.9 to 467.2 nm for these lipid nanoparticles, all of which were spherical and smooth on the outside. There was a maximum in vitro drug release of 92.6% in 24 h, a drug content of 45–55%, and a maximum entrapment efficacy of 78.6 percent. When administered through the nose, RZT benzoate may be more bioavailable than when taken orally, overcoming the first-pass impact and allowing for a long-term therapy plan for acute migraine.